Please assess the completion status of the following clinical trial:

Trial Title: Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Phase I~1. Age ≥ 18 years old~2. Ph+ CML patients who are resistant at chronic, accelerate, and acute phase, or suboptimal responsive, or intolerant to imatinib or resistant or intolerant to at least one second-generation targeted anticancer agent while being resistant, suboptimal responsive, or intolerant to imatinib simultaneously.~3. WHO Performance status of ≤2~4. Patients must have the following laboratory values With normal liver and renal function~5. Patients who have received interferon, other anti cancer drug or radiotherapy \> 1 week prior to starting study drug.~Phase II~1. Age ≥ 18 years old~2. Ph+ CML patients in chronic or accelerated phase who are resistant or intolerant to Imatinib mesylate~3. WHO Performance status of ≤2~4. Patients must have the following laboratory values With normal liver and renal function~5. Patients who have received interferon, other anti cancer drug or radiotherapy \> 1 week prior to starting study drug.~Exclusion Criteria:~Phase I~1. CNS infiltration~2. Impaired cardiac function, including any one of the followings.~   * LVEF \<45% as determined by MUGA scan or echocardiogram~  * Clinically significant resting bradycardia~3. Severe GI disease that may cause drug absorption problem of study drug~4. Use of therapeutic Warfarin~5. Acute or chronic liver or renal disease~6. Other concurrent severe and/or uncontrolled medical conditions~7. Treatment with any hematopoietic colony-stimulating growth factors ≤1 week prior to starting study drug.~8. Patients who are currently receiving treatment with medications have the potential to prolong the QT interval~9. Patients who have received Imatinib, interferon, other anti cancer drug or chemotherapy ≤ 1 week~10. Patients who have received Nilotinib and Dasatinib ≤4 weeks prior to starting study drug.~11. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy~12. Patients who are pregnant or breast-feeding or adults of reproductive potential not employing an effective method of birth control.~13. Patients not to agree using birth control during the study and for up 3 months following study completion.~15. HIV infection~Phase II~1. Blast phase CML~2. CNS infiltration~3. Impaired cardiac function, including any one of the following~   * LVEF\< 45% as determined by MUGA scan or echocardiogram~  * Use of Cardiac pacemaker~  * ST depression \> 1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads~  * Congenital long QT syndrome~  * History of, or presence of significant ventricular or atrial tachyarrhythmias~  * Clinically significant resting bradycardia~  * QTcF\> 480 msec on screening ECG~  * Right bundle branch block + left anterior hemiblock, Bifascicular block~  * Angina pectoris~4. Severe GI disease that may cause drug absorption problem of study~5. Use of therapeutic Warfarin~6. Acute or chronic liver or renal disease~7. Other concurrent severe and/or uncontrolled medical conditions~8. Treatment with any hematopoietic colony-stimulating growth factors ≤1 week prior to starting study drug.~9. Patients who are currently receiving treatment with medications have the potential to prolong the QT interval~10. Patients who have received Imatinib, interferon, other anti cancer drug or chemotherapy ≤ 1 week~11. Patients who have received wide field radiotherapy ≤4 weeks prior to starting study drug.~12. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy~13. Patients who are pregnant or breast-feeding or adults of reproductive potential not employing an effective method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radotinib (Type: EXPERIMENTAL): Phase 1 : 200mg/kg or 1200mg/m\^2~Phase 2 : 400mg Bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete